Cinaciguat Explained

Cinaciguat (BAY 58-2667) is an experimental drug for the treatment of acute decompensated heart failure.

Mechanism of action

Cinaciguat activates the soluble guanylate cyclase (sGC) which is a receptor for nitric oxide. This increases biosynthesis of cyclic GMP, resulting in vasodilation.^[1]

See also

• Riociguat, another drug stimulating sGC, but with a different mechanism
• PDE5 inhibitors act further downstream in the nitric oxide signalling pathway, reducing cyclic GMP degradation.

Notes and References

1. Schubert-Zsilavecz, M, Wurglics, M, Neue Arzneimittel 2009